Share This:
https://ntp.niehs.nih.gov/go/4424

TDMS Study 88127-06 Pathology Tables

NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01
Route: SKIN APPLICATION                                                                                           Time: 08:15:23

                                                         Final #1/Mice




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  3524-68-3

       Lock Date:  06/16/99

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:15:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Natural Death                                      2                         3            3            2            3           
    Moribund Sacrifice                                 1            1                                                   3           
  Survivors                                                                                                                         
    Terminal Sacrifice                                12           14           12           12           13            9           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
   Salivary Glands                                                                                                     (1)          
      Carcinoma                                                                                                         1 (100%)    
   Stomach, Forestomach                               (15)         (15)         (15)         (15)         (15)         (15)         
      Squamous Cell Papilloma                          2 (13%)      4 (27%)      5 (33%)      4 (27%)      6 (40%)      3 (20%)     
      Squamous Cell Papilloma, Multiple                3 (20%)                                3 (20%)      1 (7%)       1 (7%)      
   Tooth                                              (4)                       (3)          (3)          (1)                       
      Odontogenic Tumor                                4 (100%)                  3 (100%)     2 (67%)      1 (100%)                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
   Adrenal Medulla                                    (15)         (15)         (15)         (14)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
      Pheochromocytoma Benign                                                    1 (7%)                                             
   Pituitary Gland                                    (15)         (15)         (14)         (15)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:15:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
   Uterus                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                                       
   Vagina                                                                                                 (1)                       
      Squamous Cell Papilloma                                                                              1 (100%)                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node                                         (15)         (14)         (13)         (12)         (15)         (14)         
      Mediastinal, Leukemia Erythrocytic               1 (7%)                                                                       
   Lymph Node, Mandibular                             (15)         (15)         (15)         (15)         (15)         (13)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (8%)      
   Lymph Node, Mesenteric                             (14)         (15)         (15)         (14)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
   Spleen                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
   Thymus                                             (15)         (15)         (15)         (14)         (14)         (15)         
      Lymphoma Malignant                                                                      1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Squamous Cell Papilloma, Multiple                                                                    1 (7%)                   
      Skin, Site of Application, Keratoacanthoma                                                                        1 (7%)      
      Skin, Site of Application, Squamous Cell                                                                                      
          Carcinoma                                                                                                     1 (7%)      
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma                                                                           3 (20%)                               
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma, Multiple                                                    1 (7%)       7 (47%)     12 (80%)     13 (87%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:15:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                                             1 (7%)      
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)        *(15)         
      Leukemia Erythrocytic                            1 (7%)                                                           1 (7%)      
      Lymphoma Malignant                                                                      1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:15:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)             9           4           6          13          13          14               
     Total Primary Neoplasms                           10           4          10          20          22          21               
                                                                                                                                    
   Total Animals with Benign Neoplasms                  5           4           6          11          13          13               
     Total Benign Neoplasms                             5           4           7          17          21          18               
                                                                                                                                    
   Total Animals with Malignant Neoplasms               1                                   1                       3               
     Total Malignant Neoplasms                          1                                   1                       3               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                                                                          
     Total Metastatic Neoplasm                                                                                                      
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                  4                       3           2           1                           
     Total Uncertain Neoplasms                          4                       3           2           1                           
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:15:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Natural Death                                      3                                                   2            5           
    Moribund Sacrifice                                              1                                      1                        
  Survivors                                                                                                                         
    Terminal Sacrifice                                12           14           15           15           12           10           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                                             1 (7%)      
   Salivary Glands                                    (1)          (1)                       (1)                       (1)          
      Carcinoma                                        1 (100%)     1 (100%)                  1 (100%)                  1 (100%)    
   Stomach, Forestomach                               (15)         (15)         (15)         (15)         (15)         (15)         
      Squamous Cell Papilloma                          2 (13%)      3 (20%)      5 (33%)      5 (33%)      5 (33%)      3 (20%)     
      Squamous Cell Papilloma, Multiple                4 (27%)      1 (7%)                    3 (20%)                   2 (13%)     
   Tooth                                              (2)                       (3)          (1)          (3)          (2)          
      Odontogenic Tumor                                2 (100%)                  3 (100%)     1 (100%)     3 (100%)     2 (100%)    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:15:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Spleen                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                                             1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Squamous Cell Papilloma, Multiple                                                                                 1 (7%)      
      Skin, Site of Application, Keratoacanthoma                                              2 (13%)      2 (13%)      2 (13%)     
      Skin, Site of Application, Keratoacanthoma,                                                                                   
           Multiple                                                                                        1 (7%)       4 (27%)     
      Skin, Site of Application, Squamous Cell                                                                                      
          Carcinoma                                                                           2 (13%)                   2 (13%)     
      Skin, Site of Application, Squamous Cell                                                                                      
          Carcinoma, Multiple                                                                                           1 (7%)      
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma                                    1 (7%)                    4 (27%)      4 (27%)                               
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma, Multiple                                                                11 (73%)     15 (100%)    13 (87%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:15:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Alveolar/Bronchiolar Adenoma                     2 (13%)      1 (7%)                                                          
      Carcinoma, Metastatic, Salivary Glands                        1 (7%)                                                          
      Leukemia Erythrocytic                                                                                             1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Leukemia Erythrocytic                                                                                             1 (7%)      
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(15)        *(15)        *(15)        *(15)        *(15)        *(15)         
      Leukemia Erythrocytic                                                                                             1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 88127-06               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: SUBCHRON 26-WEEK                        PENTAERYTHRITOL TRIACRYLATE (PETA)                            Date: 01/10/01  
Route: SKIN APPLICATION                                                                                           Time: 08:15:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)             9           5           9          15          15          13               
     Total Primary Neoplasms                           12           6          12          29          26          32               
                                                                                                                                    
   Total Animals with Benign Neoplasms                  7           5           8          15          15          13               
     Total Benign Neoplasms                             9           5           9          25          23          25               
                                                                                                                                    
   Total Animals with Malignant Neoplasms               1           1                       3                       5               
     Total Malignant Neoplasms                          1           1                       3                       5               
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                          1                                                               
     Total Metastatic Neoplasm                                      1                                                               
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                  2                       3           1           3           2               
     Total Uncertain Neoplasms                          2                       3           1           3           2               
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------